Adial Pharmaceuticals Management
Management criteria checks 1/4
Adial Pharmaceuticals' CEO is Cary Claiborne, appointed in Aug 2022, has a tenure of 2.75 years. total yearly compensation is $976.34K, comprised of 49.7% salary and 50.3% bonuses, including company stock and options. directly owns 0.92% of the company’s shares, worth $42.10K. The average tenure of the management team and the board of directors is 1.3 years and 7.8 years respectively.
Key information
Cary Claiborne
Chief executive officer
US$976.3k
Total compensation
| CEO salary percentage | 49.7% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.9% |
| Management average tenure | 1.3yrs |
| Board average tenure | 7.8yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2024 | US$976k | US$486k | -US$13m |
| Sep 30 2024 | n/a | n/a | -US$13m |
| Jun 30 2024 | n/a | n/a | -US$12m |
| Mar 31 2024 | n/a | n/a | -US$11m |
| Dec 31 2023 | US$802k | US$466k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$8m |
| Jun 30 2023 | n/a | n/a | -US$9m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$1m | US$357k | -US$11m |
| Sep 30 2022 | n/a | n/a | -US$14m |
| Jun 30 2022 | n/a | n/a | -US$16m |
| Mar 31 2022 | n/a | n/a | -US$17m |
| Dec 31 2021 | US$688k | US$15k | -US$19m |
Compensation vs Market: Cary's total compensation ($USD976.34K) is above average for companies of similar size in the US market ($USD682.63K).
Compensation vs Earnings: Cary's compensation has increased whilst the company is unprofitable.
CEO
Cary Claiborne (63 yo)
2.8yrs
Tenure
US$976,339
Compensation
Mr. Cary John Claiborne, MBA, is the Owner and Chief Executive Officer of Prosperity Capital Management LLC. He serves as an Independent Director at LadRx Corporation (formerly known as CytRx Corporation)...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.8yrs | US$976.34k | 0.92% $ 42.1k | |
| COO & Director | 1.3yrs | US$376.20k | 0.0053% $ 242.2 | |
| CFO & Treasurer | less than a year | no data | no data | |
| Chief Legal Officer | 4.3yrs | no data | no data | |
| Vice President of Corporate Development | no data | no data | no data | |
| Acting Chief Medical Officer | no data | no data | no data | |
| Controller | less than a year | no data | no data |
1.3yrs
Average Tenure
60.5yo
Average Age
Experienced Management: ADIL's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 3.5yrs | US$976.34k | 0.92% $ 42.1k | |
| COO & Director | 7.8yrs | US$376.20k | 0.0053% $ 242.2 | |
| Chairman & Lead Independent Director | 9.1yrs | US$63.63k | 0.012% $ 568.7 | |
| Independent Director | 10.7yrs | US$57.63k | 0.21% $ 9.4k | |
| Independent Director | 10.7yrs | US$57.63k | 0% $ 0 | |
| Independent Director | 10.3yrs | US$63.63k | 0% $ 0 | |
| Chairperson of Scientific Advisory Board | 6.5yrs | no data | no data | |
| Member of the Scientific Advisory Board | 6.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 6.3yrs | no data | no data |
7.8yrs
Average Tenure
61.5yo
Average Age
Experienced Board: ADIL's board of directors are considered experienced (7.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/07 06:59 |
| End of Day Share Price | 2025/05/07 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Adial Pharmaceuticals, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kumaraguru Raja | Brookline Capital Markets |
| Brian Kemp Dolliver | Brookline Capital Markets |
| Theodore O'Neill | Litchfield Hills Research, LLC |